Skip to main content
Clinical Trials/IRCT20191213045717N1
IRCT20191213045717N1
Recruiting
Phase 3

Comparative Trial of Botulinum Toxin Type A and Methylprednisolone for The Treatment of Piriformis Syndrome

Iran University of Medical Sciences0 sites30 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Iran University of Medical Sciences
Enrollment
30
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • The patients age : 20 years or older
  • Screening of patients for clinically significant Lumbar disk herniation or Lumbosacral radiculopathy by Magnetic Resonance Imaging
  • Trigger point and tenderness in their Gluteal area
  • Pain in their buttocks radiating toward their thigh or lower limb and increasing with prolonged sitting and walking and during bending
  • Increased pain through passive forced hip flexion, adduction, and internal rotation (FAIR position), and pain when the leg was flexed at the knee and the hip was passively and medially rotated (Freiberg test)
  • Having pain for more than 3 months despite the conservative treatment and those whose individual minimum pain severity scores will be greater than 5 on a 10\-point numeric rating scale (VAS criteria)

Exclusion Criteria

  • Known allergy or sensitivity to botulinum toxin type A
  • Previous use of botulinum toxin type A or B
  • Current or planned pregnancy
  • Disorders affecting the Neuromuscular junction or Motor neuron disease,Neurologic deficits found during Electromyelography
  • Administration of Amino\- Glycosides or other drugs that interfere with Neuromuscular transmission
  • Previous Micro\- surgery or Macro\-surgery for disc disease, and any Epidural block within 7 weeks of enrollment

Outcomes

Primary Outcomes

Not specified

Similar Trials